881

    500124

    DRREDDY

    img img img img
    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    DR. REDDY S LABORATORIES Share Price Today

    DR. REDDY S LABORATORIES is currently trading at ₹1151.7, down by ₹14.6 from the previous close. The stock touched an intraday high of ₹1166.30 and a low of ₹1131.40 during the latest trading session. Over the past one year, DR. REDDY S LABORATORIES has delivered a loss of 8.99%, while the stock has declined 13.3% in the last one month.

    DR. REDDY S LABORATORIES performance

    Today’s low Today’s high
    ₹ 1131.40 ₹ 1166.30
    ₹ 1151.70
    52 week low 52 week high
    ₹ 1101.00 ₹ 1414.90
    ₹ 1151.70
    Open Price ₹ 1147.00
    Prev. Close ₹ 1166.30
    Volume (Shares) 4750512.00
    Total traded value ₹ 54711.64
    Upper Circuit ₹ 1282.90
    Lower Circuit ₹ 1049.70
    info

    Investment Returns

    Over 1 Month -13.30% Over 3 Months -12.55% Over 6 Months -7.10% Over 1 Year -8.99%
    demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    DR. REDDY S LABORATORIES fundamentals


    • Market cap (Cr) 96,129.60
    • P/E Ratio (TTM) 144.98
    • Beta 0.52
    • Book Value / share 377.95
    • Return on equity 10.69%
    • EPS (TTM) 7.95
    • Dividend yield 0.69%
    • Net profit/quarter (Cr) 404.70
    info icon alternate text
    • Market cap (Cr) 96,204.70
    • P/E Ratio (TTM) 144.98
    • Beta 0.47
    • Book Value / share 377.95
    • Return on equity 10.69%
    • EPS (TTM) 7.95
    • Dividend yield 0.69%
    • Net profit/quarter (Cr) 404.70
    info icon alternate text

    DR. REDDY S LABORATORIES Financials

    • Key Results
    • Key Ratios
    • Balance sheet
    • Cash Flow
    • Competition
    Open financial information
    Revenue
    Net income
    Particulars JUN 2026 (Values in Cr)
    Revenue 5115.00
    Operating Expense 5080.00
    Net Profit 404.70
    Net Profit Margin (%) 7.91
    Earnings Per Share (EPS) 4.86
    EBITDA 887.80
    Effective Tax Rate (%) 18.57
    Particulars MAR 2026 (Values in Cr)
    Revenue 3802.60
    Operating Expense 4694.70
    Net Profit -219.40
    Net Profit Margin (%) -5.76
    Earnings Per Share (EPS) -2.63
    EBITDA 67.30
    Effective Tax Rate (%) 28.18
    Particulars DEC 2025 (Values in Cr)
    Revenue 4266.40
    Operating Expense 4538.79
    Net Profit 90.60
    Net Profit Margin (%) 2.12
    Earnings Per Share (EPS) 1.09
    EBITDA 459.90
    Effective Tax Rate (%) 13.05
    Particulars SEP 2025 (Values in Cr)
    Revenue 4602.90
    Operating Expense 4466.50
    Net Profit 387.30
    Net Profit Margin (%) 8.41
    Earnings Per Share (EPS) 4.65
    EBITDA 844.50
    Effective Tax Rate (%) 24.98
    Particulars JUN 2025 (Values in Cr)
    Revenue 7788.70
    Operating Expense 4271.50
    Net Profit 2961.20
    Net Profit Margin (%) 38.01
    Earnings Per Share (EPS) 35.59
    EBITDA 4235.30
    Effective Tax Rate (%) 24.77
    Particulars MAR 2026 (Values in Cr)
    Revenue 20460.60
    Operating Expense 17971.10
    Net Profit 3219.70
    Net Profit Margin (%) 15.73
    Earnings Per Share (EPS) 38.68
    EBITDA 5607.00
    Effective Tax Rate (%) 24.26
    Particulars MAR 2025 (Values in Cr)
    Revenue 23046.80
    Operating Expense 16882.90
    Net Profit 5349.40
    Net Profit Margin (%) 23.21
    Earnings Per Share (EPS) 64.22
    EBITDA 8385.19
    Effective Tax Rate (%) 26.07
    Particulars MAR 2024 (Values in Cr)
    Revenue 19404.10
    Operating Expense 14554.80
    Net Profit 4342.00
    Net Profit Margin (%) 22.37
    Earnings Per Share (EPS) 260.95
    EBITDA 6788.70
    Effective Tax Rate (%) 25.02
    Particulars MAR 2023 (Values in Cr)
    Revenue 16899.10
    Operating Expense 13687.80
    Net Profit 2612.80
    Net Profit Margin (%) 15.46
    Earnings Per Share (EPS) 157.37
    EBITDA 4806.10
    Effective Tax Rate (%) 32.41
    Particulars MAR 2022 (Values in Cr)
    Revenue 14315.30
    Operating Expense 12663.40
    Net Profit 1623.20
    Net Profit Margin (%) 11.33
    Earnings Per Share (EPS) 97.85
    EBITDA 3076.10
    Effective Tax Rate (%) 27.00
    Particulars MAR 2026 (Values in Cr)
    Book Value / Share 455.96
    ROE % 11.64
    ROCE % 13.65
    Total Debt to Total Equity 0.17
    EBITDA Margin 23.22
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 404.99
    ROE % 18.53
    ROCE % 23.05
    Total Debt to Total Equity 0.11
    EBITDA Margin 29.61
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 1693.93
    ROE % 21.64
    ROCE % 26.59
    Total Debt to Total Equity 0.06
    EBITDA Margin 31.57
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 1405.34
    ROE % 21.21
    ROCE % 25.99
    Total Debt to Total Equity 0.11
    EBITDA Margin 30.16
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 1164.21
    ROE % 11.84
    ROCE % 14.46
    Total Debt to Total Equity 0.17
    EBITDA Margin 20.06
    Particulars MAR 2026 (Values in Cr)
    Book Value / Share 377.81
    ROE % 10.69
    ROCE % 12.59
    Total Debt to Total Equity 0.15
    EBITDA Margin 27.31
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 348.72
    ROE % 20.15
    ROCE % 25.47
    Total Debt to Total Equity 0.08
    EBITDA Margin 36.28
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 1453.29
    ROE % 19.42
    ROCE % 25.40
    Total Debt to Total Equity 0.02
    EBITDA Margin 34.84
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 1236.56
    ROE % 13.46
    ROCE % 18.82
    Total Debt to Total Equity 0.06
    EBITDA Margin 28.33
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 1111.56
    ROE % 9.19
    ROCE % 11.63
    Total Debt to Total Equity 0.10
    EBITDA Margin 21.35
    Particulars MAR 2026 (Values in Cr)
    Cash & Short Term Investments 3348.70
    Total Assets 58123.40
    Total Liabilities 58123.40
    Total Equity 38230.90
    Share Outstanding 83
    Price to Book Ratio 3.32
    Return on Assets (%) 7.21
    Return on Capital (%) 9.42
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 2460.20
    Total Assets 49426.60
    Total Liabilities 49426.60
    Total Equity 33927.40
    Share Outstanding 83
    Price to Book Ratio 3.28
    Return on Assets (%) 11.44
    Return on Capital (%) 14.84
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 1727.70
    Total Assets 38863.80
    Total Liabilities 38863.80
    Total Equity 28254.80
    Share Outstanding 16
    Price to Book Ratio 4.24
    Return on Assets (%) 14.35
    Return on Capital (%) 18.65
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 1730.20
    Total Assets 32285.10
    Total Liabilities 32285.10
    Total Equity 23286.10
    Share Outstanding 16
    Price to Book Ratio 3.74
    Return on Assets (%) 13.96
    Return on Capital (%) 18.47
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 2419.20
    Total Assets 29746.90
    Total Liabilities 29746.90
    Total Equity 19212.40
    Share Outstanding 16
    Price to Book Ratio 3.87
    Return on Assets (%) 7.33
    Return on Capital (%) 9.79
    Particulars MAR 2026 (Values in Cr)
    Cash & Short Term Investments 1957.60
    Total Assets 43602.10
    Total Liabilities 43602.10
    Total Equity 31365.60
    Share Outstanding 83
    Price to Book Ratio 3.32
    Return on Assets (%) 7.38
    Return on Capital (%) 8.75
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 976.80
    Total Assets 38290.90
    Total Liabilities 38290.90
    Total Equity 28856.60
    Share Outstanding 83
    Price to Book Ratio 3.28
    Return on Assets (%) 13.97
    Return on Capital (%) 16.59
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 1216.90
    Total Assets 30359.30
    Total Liabilities 30359.30
    Total Equity 24240.80
    Share Outstanding 16
    Price to Book Ratio 4.24
    Return on Assets (%) 14.30
    Return on Capital (%) 17.4
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 645.80
    Total Assets 25374.80
    Total Liabilities 25374.80
    Total Equity 20474.20
    Share Outstanding 16
    Price to Book Ratio 3.74
    Return on Assets (%) 10.29
    Return on Capital (%) 12.76
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 2030.50
    Total Assets 24495.60
    Total Liabilities 24495.60
    Total Equity 18336.20
    Share Outstanding 16
    Price to Book Ratio 3.87
    Return on Assets (%) 6.62
    Return on Capital (%) 7.92
    Particulars MAR 2026 (Values in Cr)
    Net Income 5392.70
    Cash from Operations 7026.30
    Cash from Investing -6549.30
    Cash from Financing 829.00
    Net change in Cash -46.60
    Free Cash Flow 9356.90
    Particulars MAR 2025 (Values in Cr)
    Net Income 7679.50
    Cash from Operations 6642.10
    Cash from Investing -5807.70
    Cash from Financing 1891.10
    Net change in Cash 726.20
    Free Cash Flow 9392.50
    Particulars MAR 2024 (Values in Cr)
    Net Income 7201.00
    Cash from Operations 6548.00
    Cash from Investing -4028.30
    Cash from Financing -376.30
    Net change in Cash 138.70
    Free Cash Flow 8188.30
    Particulars MAR 2023 (Values in Cr)
    Net Income 6048.50
    Cash from Operations 6958.90
    Cash from Investing -4137.30
    Cash from Financing -2686.10
    Net change in Cash -935.90
    Free Cash Flow 8091.20
    Particulars MAR 2022 (Values in Cr)
    Net Income 3061.40
    Cash from Operations 3554.50
    Cash from Investing -2638.70
    Cash from Financing -242.20
    Net change in Cash -70.10
    Free Cash Flow 5020.50
    Particulars MAR 2026 (Values in Cr)
    Net Income 4251.30
    Cash from Operations 5607.80
    Cash from Investing -5784.70
    Cash from Financing 1116.80
    Net change in Cash -7.40
    Free Cash Flow 7657.00
    Particulars MAR 2025 (Values in Cr)
    Net Income 7235.90
    Cash from Operations 5811.40
    Cash from Investing -5697.60
    Cash from Financing 1590.70
    Net change in Cash 118.10
    Free Cash Flow 8150.70
    Particulars MAR 2024 (Values in Cr)
    Net Income 5791.30
    Cash from Operations 4769.20
    Cash from Investing -3430.30
    Cash from Financing 68.10
    Net change in Cash 87.50
    Free Cash Flow 6130.29
    Particulars MAR 2023 (Values in Cr)
    Net Income 3866.00
    Cash from Operations 5835.60
    Cash from Investing -3447.60
    Cash from Financing -2696.90
    Net change in Cash -1091.60
    Free Cash Flow 6835.80
    Particulars MAR 2022 (Values in Cr)
    Net Income 2223.80
    Cash from Operations 1827.50
    Cash from Investing -2038.00
    Cash from Financing 505.50
    Net change in Cash -193.80
    Free Cash Flow 3138.80
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENTERPRISES L 32.45 13.46 1.57 248.68 23.12 38.85
    BLISS GVS PHARMA LTD 463.55 37.26 4.12 4916.24 118.35 552.90
    CIPLA LTD. 1410.90 31.85 3.31 113978.90 1165.55 1672.20
    FERMENTA BIOTECH LTD. 432.60 20.23 3.13 1273.18 256.40 480.00
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENTERPRISES L 32.45 22.69 4.18 248.68 23.12 38.85
    AMRUTANJAN HEALTH CARE LTD. 510.50 22.88 3.98 1475.89 490.00 789.95
    ASTRAZENECA PHARMA IND LT 8000.10 104.55 22.91 20000.25 7630.00 9850.00
    BLISS GVS PHARMA LTD 463.55 50.11 4.25 4916.24 118.35 552.90

    DR. REDDY S LABORATORIES shareholding pattern

    Holding
    9.55%
    26.63%
    32.07%
    31.73%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    News

    Left Arrow
    Right Arrow

    DR. REDDY S LABORATORIES Technicals Summary

    • EMA & SMA
    • Resistance and Support
    • Delivery and Volume
    • Beta
    • Price Change Analysis
    1151.70 -1.25 redarrow
    red-green-graph indicator
    16 Bearish
    0 Bullish
    • 5 Days 1180.70
    • 26 Days 1253.10
    • 10 Days 1208.30
    • 50 Days 1270.50
    • 12 Days 1217.30
    • 100 Days 1274.40
    • 20 Days 1242.30
    • 200 Days 1271.10
    1146.30 PIVOT
    First Support 1121.00 First Resistance 1191.60 Second Support 1075.70 Second Resistance 1216.90 Third Support 1050.40 Third Resistance 1262.20
    RSI 25.61 ADX 24.27 MACD -35.79 Williams % R -82.02 Commodity Channel Index (CCI) -116.90
    Date 2026-07-24 Week 1676782.00 Same Day 2668305.00 Month 1471859.00
    1 Year 0.53 3 Year 0.53
    Over 1 Month
    -13.30% down
    Over 1 Year
    -8.99% down
    Over 3 Months
    -12.55% down
    Over 3 Years
    2.21% down
    Over 6 Months
    -7.10% down
    Over 5 Years
    1.25% down

    DR. REDDY S LABORATORIES Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    10 Jul 2026 8.0 Final 10 Jul 2026 Equity shares
    10 Jul 2025 8.0 Final 10 Jul 2025 Equity shares
    16 Jul 2024 40.0 Final 17 Jul 2024 Equity shares
    11 Jul 2023 40.0 Final 12 Jul 2023 Equity shares
    11 Jul 2022 30.0 Final 13 Jul 2022 Equity shares
    09 Jul 2021 25.0 Final 13 Jul 2021 Equity shares
    13 Jul 2020 25.0 Final 15 Jul 2020 Equity shares
    15 Jul 2019 20.0 Final 17 Jul 2019 Equity shares
    16 Jul 2018 20.0 Final 18 Jul 2018 Equity shares
    17 Jul 2017 20.0 Final 19 Jul 2017 Equity shares
    18 Jul 2016 20.0 Final 20 Jul 2016 Equity shares
    10 Jul 2015 20.0 Final 14 Jul 2015 Equity shares
    11 Jul 2014 18.0 Final 15 Jul 2014 Equity shares
    12 Jul 2013 15.0 Final 16 Jul 2013 Equity shares
    28 Jun 2012 13.75 Final 03 Jul 2012 Equity shares
    30 Jun 2011 11.25 Final 05 Jul 2011 Equity shares
    02 Jul 2010 11.25 Final 06 Jul 2010 Equity shares
    03 Jul 2009 6.25 Final 07 Jul 2009 Equity shares
    04 Jul 2008 3.75 Final 08 Jul 2008 Equity shares
    06 Jul 2007 3.75 Final 10 Jul 2007 Equity shares
    07 Jul 2006 0.0 Final 11 Jul 2006 Equity shares
    07 Jul 2005 0.0 Final 11 Jul 2005 Equity shares
    Ex-Date Ex-Bonus Ratio
    29 Aug 2006 28 Aug 2006 1:1
    03 May 1994 08 Apr 1994 2:1
    Ex-Date Old FV NEW FV Record Date
    28 Oct 2024 5.0 1.0 28 Oct 2024
    10 Oct 2001 10.0 5.0 25 Oct 2001
    Dividend date Dividend amount Dividend type Record date Instrument type
    10 Jul 2026 8.0 Final 10 Jul 2026 Equity shares
    10 Jul 2025 8.0 Final 10 Jul 2025 Equity shares
    16 Jul 2024 40.0 Final 17 Jul 2024 Equity shares
    11 Jul 2023 40.0 Final 12 Jul 2023 Equity shares
    11 Jul 2022 30.0 Final 13 Jul 2022 Equity shares
    09 Jul 2021 25.0 Final 13 Jul 2021 Equity shares
    13 Jul 2020 25.0 Final 15 Jul 2020 Equity shares
    15 Jul 2019 20.0 Final 17 Jul 2019 Equity shares
    16 Jul 2018 20.0 Final 18 Jul 2018 Equity shares
    17 Jul 2017 20.0 Final 19 Jul 2017 Equity shares
    18 Jul 2016 20.0 Final 20 Jul 2016 Equity shares
    10 Jul 2015 20.0 Final 14 Jul 2015 Equity shares
    11 Jul 2014 18.0 Final 15 Jul 2014 Equity shares
    12 Jul 2013 15.0 Final 16 Jul 2013 Equity shares
    28 Jun 2012 13.75 Final 03 Jul 2012 Equity shares
    30 Jun 2011 11.25 Final 05 Jul 2011 Equity shares
    02 Jul 2010 11.25 Final 06 Jul 2010 Equity shares
    03 Jul 2009 6.25 Final 07 Jul 2009 Equity shares
    04 Jul 2008 3.75 Final 08 Jul 2008 Equity shares
    06 Jul 2007 3.75 Final 10 Jul 2007 Equity shares
    07 Jul 2006 0.0 Final 11 Jul 2006 Equity shares
    07 Jul 2005 0.0 Final 11 Jul 2005 Equity shares
    Ex-Date Ex-Bonus Ratio
    29 Aug 2006 28 Aug 2006 1:1
    03 May 1994 08 Apr 1994 2:1
    Ex-Date Old FV NEW FV Record Date
    28 Oct 2024 5.0 1.0 28 Oct 2024
    10 Oct 2001 10.0 5.0 25 Oct 2001

    Top Gainers

    Top Losers

    Dr. Reddy's Laboratories share result highlights

    Dr. Reddy’s Laboratories posted consolidated sales of ₹8,572 crore in Q1 FY25-26 versus ₹7,696 crore in Q1 FY24-25. Expenses stood at ₹6,398 crore in Q1 FY25-26 against ₹5,566 crore in Q1 FY24-25. Operating profit was ₹2,174 crore in Q1 FY25-26 compared with ₹2,130 crore in Q1 FY24-25. Net profit was recorded at ₹1,410 crore in Q1 FY25-26 versus ₹1,392 crore in Q1 FY24-25.

    Date Source: screener.in, and corporate filings on NSE/BSE

    Dr. Reddy's Laboratories share annual reports

    Dr. Reddy’s Laboratories reported consolidated sales of ₹32,644 crore in FY24-25 versus ₹28,011 crore in FY23-24. Expenses stood at ₹24,097 crore in FY24-25 against ₹20,078 crore in FY23-24. Operating profit was ₹8,547 crore in FY24-25 compared with ₹7,933 crore in FY23-24. Net profit was recorded at ₹5,725 crore in FY24-25 versus ₹5,578 crore in FY23-24.

    Date Source: screener.in, and corporate filings on NSE/BSE

    Dr. Reddy's Laboratories share dividend

    Dr. Reddy’s Laboratories paid a dividend of ₹8 per share with ex-date of 10 Jul 2025. In the previous year, the company paid ₹40 per share on 16 Jul 2024. Earlier, it paid ₹40 per share on 11 Jul 2023, ₹30 per share on 11 Jul 2022, ₹25 per share on 9 Jul 2021, ₹25 per share on 13 Jul 2020, and ₹20 per share on 15 Jul 2019.

    Date Source: screener.in, and corporate filings on NSE/BSE

    stock
    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Dr Reddys Laboratories Ltd?

    Answer Field

    Dr Reddys Laboratories Ltd share price is for NSE ₹ 1,151.70 & for BSE ₹ 1,152.60 as on Jul 24 2026 03:30 PM.

    What is the Market Cap of Dr Reddys Laboratories Ltd Share?

    Answer Field

    The market cap of Dr Reddys Laboratories Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jul 24 2026 03:30 PM.

    What is the 52 Week High and Low of Dr Reddys Laboratories Ltd?

    Answer Field

    The 52 Week High and Low of Dr Reddys Laboratories Ltd for NSE is ₹ 1,414.90 and ₹ 1,101.00 and for BSE is ₹ 1,414.40 and ₹ 1,080.05.

    What is 1 year return for Dr Reddys Laboratories Ltd?

    Answer Field

    The 1 year returns on the stock has been -8.99%.

    What is the P/E Ratio of Dr Reddys Laboratories Ltd Share?

    Answer Field

    As on Jul 24 2026 03:30 PM the price-to-earnings (PE) ratio for Dr Reddys Laboratories Ltd share is 144.98.

    What is the PB ratio of Dr Reddys Laboratories Ltd Share?

    Answer Field

    As on Jul 24 2026 03:30 PM, the price-to-book (PB) ratio for Dr Reddys Laboratories Ltd share is 377.95.

    How to Buy Dr Reddys Laboratories Ltd Share?

    Answer Field

    You can trade in Dr Reddys Laboratories Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Dr Reddys Laboratories Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Dr Reddys Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

    • Login to the Bajaj Broking App

    • Click on the Search Icon

    • Search “Dr Reddys Laboratories Ltd”

    • Click on the BUY icon

    • Place a buy order specifying the desired quantity of shares.

    • Click BUY again to complete the purchase

    Who is the CEO of Dr Reddy's Laboratories Ltd?

    Answer Field

    Erez Israeli has held the position of CEO at Dr Reddy's Laboratories Ltd since 1 Aug 2019. He leads the company in advancing pharmaceutical innovations and global market reach, focusing on sustainable growth and maintaining Dr Reddy's competitive position within the industry.

    When was Dr Reddy's Laboratories Ltd established?

    Answer Field

    Dr Reddy's Laboratories Ltd was founded in 1984 in Hyderabad, India, by Dr. Anji Reddy. The company began by manufacturing Active Pharmaceutical Ingredients (APIs) and quickly expanded to become one of India’s leading pharmaceutical companies with a significant global presence.

    What factors influence the Dr Reddy Share Price?

    Answer Field

    Dr Reddy share price is influenced by multiple factors, including financial performance, revenue growth, and profitability. Sector trends, global market conditions, regulatory changes, and investor sentiment also impact share value, shaping the overall market perception of Dr Reddy's potential for future growth.

    Is Dr Reddy's Laboratories Ltd debt free?

    Answer Field

    Dr Reddy's Laboratories Ltd is not entirely debt-free; however, the company maintains a balanced debt-to-equity ratio, ensuring debt levels remain manageable. This strategic financial management allows Dr Reddy's to invest in growth opportunities while maintaining financial stability and supporting long-term shareholder value.

    What is the CAGR of Dr Reddy Share?

    Answer Field

    The Compound Annual Growth Rate (CAGR) for Dr Reddy share is 6% over 10 years, 19% over 5 years, 10% over 3 years, and 19% over the last year. These figures reflect the company’s growth trajectory and its consistent performance in the pharmaceutical sector.

    How has the Dr Reddy Share Price performed over the past year?

    Answer Field

    Over the past year, Dr Reddy share price has demonstrated a positive performance, showing a 19% growth in CAGR. This growth highlights investor confidence and reflects the company’s strong market position, profitability, and financial resilience within the highly competitive pharmaceutical industry.

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |